Boston Scientific (NYSE:BSX) unveiled new 3-month results on its Precision Spectra spinal cord stimulation system, saying the implant resulted in significant pain reduction at 3 months and an overall success rate of 94%.
The report came from a retrospective analysis of more than 200 patients treated at 13 centers, focusing on patients with chronic pain. Patients with pain reported a reduction from a 7.8 baseline to 3.2 on average, and those with low back pain reported a reduction from a 7.0 baseline score to 2.9 on average, according to a company statement.
"The primary objective of SCS is pain relief," University Hospitals of Cleveland pain medicine division chief Dr. Salim Hayek said on behalf of the company. "These initial results indicate that the Precision Spectra System is effectively reducing pain in these real-world patients at three months post implant."
Massachusetts medtech titan Boston Scientific earlier this year won FDA approval for the Precision Plus implant with indication to treat chronic pain. The device is designed to deliver controlled electrical pulses that mask pain signals on their way to the brain. The device won CE Mark approval in the European Union late last year.